🩻 #ASCOAI: Could #AI help improve radiation oncology training? A randomized phase II trial found that AI auto-segmentation improved contour quality and efficiency among novice practitioners performing #ProstateCancer brachytherapy. Learn more 👉 ascoai.org/articles/2026/10/…

2️⃣ studies highlight emerging therapies for AL #Amyloidosis. Anselamimab showed a survival signal in prespecified subgroup, while linvoseltamab demonstrated deep hematologic and organ responses in early-phase research. 🔹Drs. Wechalekar & Lee | #ASCO26 ascopost.com/news/october-20…

🚨 #FDAApproval: The @FDA has granted accelerated approval to dostarlimab (Jemperli) for adults with stage II/III MSI-H/dMMR locally advanced #RectalCancer. In AZUR-1, the ORR was 79%, with a 47% sustained clinical CR rate at 12 months. 🔗 ascopost.com/news/october-20…

🩸In the phase III EXCALIBER-RRMM trial, iberdomide + daratumumab + dexamethasone improvedMRD-negative CR rates vs the bortezomib-based regimen (41% vs 21%) in patients with relapsed/refractory #MultipleMyeloma. 🔸@SagarLonialMD | @TheLancetOncol 🔗 ascopost.com/news/october-20…

🔍 Nearly half (48%) of patients with high-risk #Melanoma developed chronic immune-related adverse events after adjuvant anti–PD-1 therapy. ➡️ At a median follow-up of 67 months, 34% had ongoing toxicity ▪️Douglas B. Johnson, MD | @JAMANetworkOpen ascopost.com/news/october-20…

🤝@ASCO and @WHO have signed a collaboration agreement that is focused on: 1⃣ building professional competencies in #CancerCare 2⃣ improving access to #clinicaltrials 3⃣ strengthening quality, accessibility & accountability in #cancer care Learn more ➡️ ascopost.com/news/october-20…

🖥️ #ASCOAI: This week in #AI and #CancerCare: 🔹Predicting #PancreaticCancer risk years before diagnosis 🔹AI-assisted contouring benefits trainees 🔹Predicting ICI-related pneumonitis risk in #LungCancer 🎥Watch the latest news brief: ascoai.org/videos/weekly-bri…

🔬Hereditary #CancerRisk isn't limited to younger patients. Germline pathogenic variants were identified in 18.4% of early-onset, 15.6% of average-onset & 12.3% of late-onset cases, supporting broader genetic testing. 🔹Drs. Diaz & Stadler | @CD_AACR ascopost.com/news/october-20…

💆How can #Oncology teams better integrate acupuncture and massage for cancer pain? Kelly M. McConnell, PhD, and Jun J. Mao, MD, MSCE, outline how the IMAGINE project addresses training, awareness, and implementation barriers. Explore the findings ➡️ ascopost.com/news/october-20…

🖥️ #ASCOAI: A transformer-based #AI model developed at @MayoClinic predicted #PancreaticCancer risk up to 5 years before diagnosis, achieving an AUROC of 0.853. The model uses routine lab results and diagnostic histories to identify high-risk patients 🔗 ascoai.org/articles/2026/10/…

🩻 Automated breast ultrasound had similar #BreastCancer detection rates to handheld ultrasound, with fewer false-positive initial assessments ➡️Findings support ABUS as alternative for screening women with dense breasts ▪️Brian Sprague, PhD | @JACRJournal ascopost.com/news/october-20…

➕Adding sitagliptin to antithymocyte globulin–based prophylaxis reduced acute #GVHD after alternative donor transplantation. ➡️ Phase III trial found no significant improvement in 2-year overall or relapse-free survival ▪️Yang Xu, MD | @JCO_ASCO ascopost.com/news/october-20…

‍🏃‍A 12-week remote exercise program improved quality of life in 75.8% of patients receiving #Immunotherapy vs 6.3% with usual care. ➡️ Findings from a phase II trial highlight the benefits of exercise in #CancerCare 🔹@PauloBergerot | #ASCOQLTY26 🔗ascopost.com/news/october-20…

🧬Proactive outreach and navigation may improve hereditary #CancerRisk assessment In the FaCT trial, 90% of relatives receiving facilitated #BRCA 1/2 testing completed by 18 months vs 62% with standard care. 🔹Roni Nitecki Wilke, MD, MPH | @JCO_ASCO ascopost.com/news/october-20…

💰Financial toxicity remains a major challenge in #CancerCare. The CREDIT trial found that navigation support alone may not be enough for patients at greatest financial risk, highlighting a need for tailored interventions. ▪️@ShankaranVeena | #ASCOQLTY26 ascopost.com/news/october-20…

🔬#ASCOAI: Can #AI help detect #SkinCancer before it becomes clinically visible? The SUBSCAN approach combines real-time AI image recognition with noninvasive LC-OCT to identify subclinical basal cell carcinomas. ❗Researchers caution about overdiagnosis ascoai.org/articles/2026/10/…

🫁Higher abdominal fat was associated with increased #LungCancer risk in a study of 1,170 high-risk individuals. Findings challenge the “obesity paradox” and suggest central adiposity may contribute to lung carcinogenesis 🔸Dr. Sai Yendamuri | @JTOonline ascopost.com/news/october-20…

🫂#ASCOAI: The proposed PRECISION-AI framework from @SylvesterCancer outlines a path for integrating #AI into cancer survivorship #supportivecare, from symptom monitoring to psychosocial assistance. Learn more ➡️ ascoai.org/articles/2026/10/…

🩸In a phase 1️⃣ trial, investigational BCMA-directed #CARTcell therapy anito-cel achieved a 100% response rate in heavily pretreated relapsed/refractory #MultipleMyeloma, with 79% achieving complete response. 🔹Michael R. Bishop, MD | @NEJM 🔗 ascopost.com/news/october-20…

🚨 #FDAApproval: The @FDA has granted approval for expanded indication for Anktiva + BCG in BCG-unresponsive #NMIBC to include adults with high-grade papillary-only tumors. 🔗 ascopost.com/news/october-20…